Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Corporate
  5. Investments Infrastructure

Investments in Infrastructure

Evaluate

Thumbnail
May 18, 2022

Investors bite the big pharma hands that feed them

Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.

Thumbnail
July 11, 2018

Is a Pfizer break-up back on?

Vantage logo
May 31, 2018

Stryker the surprise winner in the medtech spend versus sales stakes

Vantage logo
May 30, 2018

On spend vs sales Pfizer is an outlier – but not always in a good way

Article image
Vantage logo
April 26, 2018

Interview – Boehringer does digital health, San Francisco style

Boehringer gets diggi with it.

Vantage logo
January 30, 2018

Amazon invites some friends to light a US healthcare bonfire

Article image
Vantage logo
January 09, 2018

2017 saw the stars Align for big-cap medtech

Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.

Vantage logo
November 13, 2017

Alnylam: The $12bn company with the $2bn war chest

Vantage logo
October 17, 2017

How do you solve a problem like Maria?

Vantage logo
October 05, 2016

Vantage point – What Brexit means for drug regulation

Vantage logo
August 04, 2016

Big pharma’s R&D zero-to-hero story

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up